Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Trueman, D. [1 ]
Ndirangu, K. [2 ]
Paine, A. [1 ]
Pilkington, H. [1 ]
机构：
[1] Source Hlth Econ, Hlth Econ & Stat, London, England
[2] Eisai Inc, Global Value & Access, Nutley, NJ USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1007P
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 50 条
  • [1] Network meta-analysis (NMA) of treatments for unresectable hepatocellular carcinoma (uHCC)
    Tremblay, G.
    Meier, G.
    Misurski, D.
    Baig, M.
    Tamai, T.
    Kraljevic, S.
    Shor, A.
    Forsythe, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
    Zhi, W.
    Xu, F.
    Luo, J.
    Zhang, C.
    Huang, X.
    Han, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1310 - S1310
  • [3] Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Wang, Shijie
    Wang, Yiting
    Yu, Jiangtao
    Wu, Huaxing
    Zhou, Yanming
    CANCERS, 2022, 14 (22)
  • [4] Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
    Cheng, A. -L.
    Finn, R. S.
    Qin, S.
    Han, K. -H.
    Ikeda, K.
    Piscaglia, F.
    Baron, A.
    Park, J. -W.
    Han, G.
    Jassem, J.
    Blanc, J. F.
    Vogel, A.
    Komov, D.
    Evans, T. J.
    Lopez, C.
    Dutcus, C.
    Ren, M.
    Kraljevic, S.
    Tamai, T.
    Kudo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 211 - 211
  • [5] Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)
    Cheng, Ann-Lii
    Finn, Richard S.
    Qin, Shukui
    Han, Kwan-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    MinRen
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Bower, John
    Kudo, Masatoshi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 116 - 116
  • [6] Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Cheng, Ann-Lii
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari David
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean -Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    -Lopez, Carlos Lopez
    Dutcus, Corina E.
    Ren, Min
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta-analysis
    Zhu, Gang
    Zeng, Longfei
    Yang, Liu
    Zhang, Xin
    Tang, Jinquan
    Pan, Yong
    Li, Bo
    Chen, Mengchen
    Wu, Tao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1425 - 1434
  • [8] COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Li, X.
    Wudong, G.
    Wang, Y.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [9] New First-line Immunotherapy-based Therapies for Unresectable Hepatocellular Carcinoma: A Living Network Meta-analysis
    Chen, Jian-Jian
    Jin, Zhi-Cheng
    Luo, Biao
    Wang, Yu-Qing
    Li, Rui
    Zhu, Hai -Dong
    Teng, Gao-Jun
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (01) : 15 - 24
  • [10] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Wang, Bi-Cheng
    Kuang, Bo-Hua
    Lin, Guo-He
    TARGETED ONCOLOGY, 2024, 19 (02) : 203 - 212
12345